414 related articles for article (PubMed ID: 24650305)
1. Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort.
Jung M; Bonner A; Hudson M; Baron M; Pope JE;
Scand J Rheumatol; 2014; 43(3):217-20. PubMed ID: 24650305
[TBL] [Abstract][Full Text] [Related]
2. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
3. Determinants of morbidity and mortality of systemic sclerosis in Canada.
Al-Dhaher FF; Pope JE; Ouimet JM
Semin Arthritis Rheum; 2010 Feb; 39(4):269-77. PubMed ID: 18706680
[TBL] [Abstract][Full Text] [Related]
4. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
5. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects.
Diab S; Dostrovsky N; Hudson M; Tatibouet S; Fritzler MJ; Baron M; Khalidi N;
J Rheumatol; 2014 Nov; 41(11):2179-85. PubMed ID: 25274885
[TBL] [Abstract][Full Text] [Related]
6. Low socioeconomic status (measured by education) and outcomes in systemic sclerosis: data from the Canadian Scleroderma Research Group.
Mansour S; Bonner A; Muangchan C; Hudson M; Baron M; Pope JE;
J Rheumatol; 2013 Apr; 40(4):447-54. PubMed ID: 23418377
[TBL] [Abstract][Full Text] [Related]
7. The effect of male sex on survival in systemic sclerosis.
Hussein H; Lee P; Chau C; Johnson SR
J Rheumatol; 2014 Nov; 41(11):2193-200. PubMed ID: 25274896
[TBL] [Abstract][Full Text] [Related]
8. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry.
Khimdas S; Harding S; Bonner A; Zummer B; Baron M; Pope J;
Arthritis Care Res (Hoboken); 2011 Jan; 63(1):142-9. PubMed ID: 20740608
[TBL] [Abstract][Full Text] [Related]
9. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
[TBL] [Abstract][Full Text] [Related]
10. Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody.
Guillen-Del Castillo A; Pilar Simeón-Aznar C; Fonollosa-Pla V; Alonso-Vila S; Reverte-Vinaixa MM; Muñoz X; Pallisa E; Selva-O'allaghan A; Fernández-Codina A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2014 Dec; 44(3):331-7. PubMed ID: 25110305
[TBL] [Abstract][Full Text] [Related]
11. Anti-PM-Scl antibody in patients with systemic sclerosis.
Koschik RW; Fertig N; Lucas MR; Domsic RT; Medsger TA
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S12-6. PubMed ID: 22261302
[TBL] [Abstract][Full Text] [Related]
12. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
[TBL] [Abstract][Full Text] [Related]
13. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
14. Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group.
Pope J; Harding S; Khimdas S; Bonner A; ; Baron M
J Rheumatol; 2012 Mar; 39(3):524-31. PubMed ID: 22247347
[TBL] [Abstract][Full Text] [Related]
15. Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients.
Sampaio-Barros PD; Bortoluzzo AB; Marangoni RG; Rocha LF; Del Rio AP; Samara AM; Yoshinari NH; Marques-Neto JF
J Rheumatol; 2012 Oct; 39(10):1971-8. PubMed ID: 22896025
[TBL] [Abstract][Full Text] [Related]
16. The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts.
Dougherty DH; Kwakkenbos L; Carrier ME; Salazar G; Assassi S; Baron M; Bartlett SJ; Furst DE; Gottesman K; van den Hoogen F; Malcarne VL; Mouthon L; Nielson WR; Poiraudeau S; Sauvé M; Boire G; Bruns A; Chung L; Denton C; Dunne JV; Fortin P; Frech T; Gill A; Gordon J; Herrick AL; Hinchcliff M; Hudson M; Johnson SR; Jones N; Kafaja S; Larché M; Manning J; Pope J; Spiera R; Steen V; Sutton E; Thorne C; Wilcox P; Thombs BD; Mayes MD;
Rheumatology (Oxford); 2018 Sep; 57(9):1623-1631. PubMed ID: 29868924
[TBL] [Abstract][Full Text] [Related]
17. The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile.
Vanthuyne M; Smith V; De Langhe E; Van Praet J; Arat S; Depresseux G; Westhovens R; Blockmans D; Badot V; Cogan E; De Keyser F; Houssiau FA
J Rheumatol; 2012 Nov; 39(11):2127-33. PubMed ID: 22984273
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
[TBL] [Abstract][Full Text] [Related]
19. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.
Nevskaya T; Baron M; Pope JE;
Rheumatology (Oxford); 2017 Jul; 56(7):1111-1122. PubMed ID: 28340090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
